Navigation Links
Jellyfish Protein Extends Neuroprotective Tentacles at Neuroscience Conference
Date:10/24/2009

Data presented this week at the annual meeting of the Society for Neuroscience highlighted the ability of a jellyfish protein “aequorin” to protect neurons after a stroke. In prior conferences, data from the University of Wisconsin-Milwaukee demonstrated aequorin’s ability to protect cells prior to an ischemic event. Quincy Bioscience Quincy Bioscience is a partner in the research and development of the jellyfish protein as a novel therapeutic for neurodegenerative diseases.

Chicago, IL (Vocus) October 21, 2009 -- Data presented this week at the annual meeting of the Society for Neuroscience highlighted the ability of a jellyfish protein “aequorin” to protect neurons after a stroke. In prior conferences, data from the University of Wisconsin-Milwaukee demonstrated aequorin’s ability to protect cells prior to an ischemic event. Quincy Bioscience Quincy Bioscience is a partner in the research and development of the jellyfish protein as a novel therapeutic for neurodegenerative diseases.

The data presented at the prestigious conference highlights the continuing story of an unusual compound making its presence known in the field of neuroscience. “Stroke is used in the laboratory because the model replicates a biochemical process in a few minutes what neurodegeneration takes years to do and gives us a good idea of a compound’s neuroprotective ability.” explains Mark Underwood, Quincy Bioscience president.

The neuroscience pipeline for drug development has been lacking significant breakthroughs for several years. “The bar for Alzheimer’s drugs is not very high. The existing approved drugs for Alzheimer’s have provided a small amount of improvement for the lives of patients and caregivers.”

According to the calcium hypothesis of brain aging, one of the reasons for reasons for neurodegeneration is the brain cell’s inability to regulate calcium ions. Calcium binding proteins (CaBPs) are intracellular proteins that help regulate calcium. Their decline is gradual in normal aging and is believed to contribute to elevated calcium ion levels which in turn affect brain function. Conversely, in neurodegeneration, CaBP production declines rapidly and contributes to cell death.

For people over forty years of age it is estimated that 30,000 – 50,000 brain cells die each day which can lead to cognitive challenges such as an impaired ability to learn and retain new information as well as memory loss.

Aequorin is a naturally-occurring CaBP and was first discovered in glowing jellyfish in the Puget Sound by Princeton researcher Osamu Shimomura, Ph.D. in 1962. Dr. Shimomura was one of the recipients of the Nobel Prize in Chemistry 2008 for the discovery and development of this protein for the advancement in calcium research. Aequorin’s DNA structure is very similar to the CaBPs produced in the brain. Quincy Bioscience has patent-filings for the novel use of Aequorin for the purposes of neuronal calcium regulation.

ABOUT QUINCY BIOSCIENCE
Quincy Bioscience is a biotech company located in Madison, Wisconsin focused on the discovery, development and commercialization of novel medicines to treat age related memory loss and the diseases of aging. The company's therapeutic focus is on alleviating the consequences of impaired calcium homeostasis - the imbalance of calcium ions thought to be related to neurodegenerative diseases such as Alzheimer's and Parkinson's.

# # #

Read the full story at http://www.prweb.com/releases/Brain/Health/prweb3090774.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Jellyfish Protein Shows Potential to Help With Memory
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
4. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
5. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
6. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
7. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
8. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
9. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
10. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
11. Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Jellyfish Protein Extends Neuroprotective Tentacles at Neuroscience Conference
(Date:2/19/2017)... ... February 19, 2017 , ... Expanding Portfolio to Include Lab ... equipment with the goal of expanding the reach of its quality and precision ... water analysis meters were introduced into the market in 2014. , The OHAUS ...
(Date:2/17/2017)... PUNE, India , February 17, 2017 /PRNewswire/ ... research report "Biomarkers Market by Product (Consumables, Service), ... Disorders), Application (Diagnostics Development, Drug Discovery and Development, ... MarketsandMarkets, the market is projected to reach USD ... in 2016, growing at a CAGR of 13.8% ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital has launched work ... agricultural industry. Pilot studies are about to get under way for the framework, which ... 5G innovations. The concept is expected to be transferred eventually to other industries that ...
(Date:2/16/2017)... Calif. , Feb. 16, 2017  ArmaGen, ... developing groundbreaking therapies to treat severe neurological disorders, ... children treated with AGT-181, the company,s investigational therapy ... (also known as mucopolysaccharidosis type I, or MPS ... 2 proof-of-concept (POC) study, presented today at the ...
Breaking Biology Technology:
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/26/2017)... 26, 2017  Crossmatch, a leading provider of security ... aimed at combatting fraud, waste and abuse in assistance ... the Action on Disaster Relief conference in ... UN agencies and foreign assistance organizations throughout ... abuse are a largely unacknowledged problem in the foreign ...
Breaking Biology News(10 mins):